Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity

Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3

(2014) Chiara Camisaschi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion

(2013) J. Tel et al.   JOURNAL OF IMMUNOLOGY

Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells

(2013) Nicola Gagliani et al.   NATURE MEDICINE

Anticancer TLR agonists on the ropes

(2012) Malini Guha   NATURE REVIEWS DRUG DISCOVERY

Plasmacytoid Dendritic Cells: Recent Progress and Open Questions

(2011) Boris Reizis et al.   Annual Review of Immunology

Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma

(2011) Trine O. Jensen et al.   CANCER

LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites

(2010) C. Camisaschi et al.   JOURNAL OF IMMUNOLOGY

Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

(2010) Junko Matsuzaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA